Published in Blood on January 15, 1997
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 3.20
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A (2002) 3.19
Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol (1997) 2.98
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A (2001) 2.84
SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.75
High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest (2009) 2.66
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer (2010) 2.66
Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol (2000) 2.59
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A (2002) 2.19
Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest (2003) 2.12
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol (2001) 1.70
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol (1998) 1.69
Genome sequencing and cancer. Curr Opin Genet Dev (2012) 1.68
Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest (2011) 1.66
Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am J Hum Genet (1998) 1.64
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood (2009) 1.61
C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J (2003) 1.58
A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1999) 1.50
One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett (2013) 1.49
BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med (2001) 1.47
The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol Cell Biol (1998) 1.46
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia (2016) 1.45
Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Proc Natl Acad Sci U S A (2005) 1.43
The APL paradigm and the "co-clinical trial" project. Cancer Discov (2011) 1.33
Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. J Exp Med (2005) 1.33
Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A (2000) 1.30
Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood (2008) 1.30
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol (2005) 1.21
Commonly dysregulated genes in murine APL cells. Blood (2006) 1.18
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci (2007) 1.17
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood (2006) 1.17
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med (2013) 1.15
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci U S A (2001) 1.11
Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther (2010) 1.11
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci U S A (1999) 1.10
A proteomic chronology of gene expression through the cell cycle in human myeloid leukemia cells. Elife (2014) 1.10
Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol (2004) 1.10
Haploinsufficiency for tumor suppression: the hazards of being single and living a long time. J Exp Med (2001) 1.04
Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein. Proc Natl Acad Sci U S A (1997) 1.02
The nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin Cell Biol (2011) 1.01
PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. J Clin Invest (2011) 1.00
DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth Differ (2001) 0.99
Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene (2008) 0.97
Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood (2008) 0.97
Sox4 cooperates with CREB in myeloid transformation. Blood (2012) 0.96
Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Blood (2010) 0.93
PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia. Cancer Res (2010) 0.90
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer J (2013) 0.86
The significance of low PU.1 expression in patients with acute promyelocytic leukemia. J Hematol Oncol (2012) 0.86
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2002) 0.85
The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J Clin Invest (1998) 0.84
Animal models of leukemia: any closer to the real thing? Cancer Metastasis Rev (2013) 0.84
Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice. PLoS One (2012) 0.84
Functional and structural insights into ASB2alpha, a novel regulator of integrin-dependent adhesion of hematopoietic cells. J Biol Chem (2011) 0.83
A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood (2010) 0.83
NLS-RARα promotes proliferation and inhibits differentiation in HL-60 cells. Int J Med Sci (2014) 0.83
Cross talk between retinoic acid signaling and transcription factor GATA-2. Mol Cell Biol (2004) 0.83
PML(NLS(-)) inhibits cell apoptosis and promotes proliferation in HL-60 cells. Int J Med Sci (2013) 0.81
Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation. Haematologica (2015) 0.81
Notch signaling in acute promyelocytic leukemia. Leukemia (2013) 0.79
PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. J Clin Invest (2015) 0.79
The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ (2016) 0.78
Establishment of a humanized APL model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice. PLoS One (2014) 0.78
STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes Cancer (2014) 0.78
The molecular basis of myeloid malignancies. Proc Jpn Acad Ser B Phys Biol Sci (2014) 0.78
Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RARα oncoprotein of acute promyelocytic leukemia. Proteins (2012) 0.77
Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation. Mol Cell Biol (2003) 0.77
MYC and PIM2 co-expression in mouse bone marrow cells readily establishes permanent myeloid cell lines that can induce lethal myeloid sarcoma in vivo. Mol Cells (2012) 0.77
Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD). J Biochem (2015) 0.76
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. Oncotarget (2016) 0.75
ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget (2016) 0.75
Treatment with 5-azacytidine accelerates acute promyelocytic leukemia leukemogenesis in a transgenic mouse model. Genes Cancer (2011) 0.75
PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. Leukemia (2016) 0.75
The tripartite motif family identifies cell compartments. EMBO J (2001) 9.64
The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature (1999) 7.85
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell (1994) 4.26
Targeted deletion of 5'HS2 of the murine beta-globin LCR reveals that it is not essential for proper regulation of the beta-globin locus. Genes Dev (1995) 4.11
Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med (1998) 4.04
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
The physician-scientist: career issues and challenges at the year 2000. FASEB J (2000) 3.38
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 3.20
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes Dev (1997) 3.01
RNA processing errors in patients with beta-thalassemia. Proc Natl Acad Sci U S A (1982) 2.99
Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A (1996) 2.93
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia (2013) 2.85
Long-range disruption of gene expression by a selectable marker cassette. Proc Natl Acad Sci U S A (1996) 2.83
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J (1997) 2.62
Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem (1993) 2.56
Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A (1999) 2.48
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1995) 2.43
Numb is an endocytic protein. J Cell Biol (2000) 2.39
ALK+ lymphoma: clinico-pathological findings and outcome. Blood (1999) 2.38
Inducible transcription of five globin genes in K562 human leukemia cells. Proc Natl Acad Sci U S A (1983) 2.35
Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene (1994) 2.27
Analysis of mice containing a targeted deletion of beta-globin locus control region 5' hypersensitive site 3. Mol Cell Biol (1996) 2.17
Beta O-39 thalassemia gene: a premature termination codon causes beta-mRNA deficiency without affecting cytoplasmic beta-mRNA stability. Blood (1984) 2.17
An enhancer element lies 3' to the human A gamma globin gene. EMBO J (1987) 2.11
T-cell receptor gene rearrangements as markers of lineage and clonality in T-cell neoplasms. Proc Natl Acad Sci U S A (1985) 2.10
Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09
Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A (1986) 2.09
Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell (2000) 2.02
eps15 and eps15R are essential components of the endocytic pathway. Cancer Res (1997) 1.99
Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature (1994) 1.97
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J (1994) 1.94
Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science (1995) 1.93
Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases. Proc Natl Acad Sci U S A (1992) 1.93
Conservation of the primary structure, organization, and function of the human and mouse beta-globin locus-activating regions. Proc Natl Acad Sci U S A (1990) 1.89
A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution. Proc Natl Acad Sci U S A (1995) 1.87
How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol (1998) 1.80
Evolution of Shc functions from nematode to human. Curr Opin Genet Dev (2000) 1.80
Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene (2011) 1.79
Lymphoid tumors displaying rearrangements of both immunoglobulin and T cell receptor genes. J Exp Med (1985) 1.79
Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J Biol Chem (1995) 1.77
Not all Shc's roads lead to Ras. Trends Biochem Sci (1996) 1.74
Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood (1999) 1.73
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol (1998) 1.69
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64
fgr proto-oncogene mRNA induced in B lymphocytes by Epstein-Barr virus infection. Nature (1986) 1.64
Genomic instability in induced stem cells. Cell Death Differ (2011) 1.63
5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood (1983) 1.61
Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med (1986) 1.60
Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci U S A (1995) 1.59
Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene (1992) 1.59
Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem (2001) 1.57
Molecular cloning, chromosomal localization, and bacterial expression of a murine macrophage metalloelastase. J Biol Chem (1992) 1.57
Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Science (1984) 1.56
Normal neutrophil function in cathepsin G-deficient mice. Blood (1999) 1.53
DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity (2000) 1.52
Genomic organization and chromosomal localization of the human cathepsin G gene. J Biol Chem (1989) 1.52
Advances in thalassemia research. Blood (1984) 1.52
Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood (1999) 1.50
A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1999) 1.50
Functional properties of the beta-globin locus control region in K562 erythroleukemia cells. Blood (1991) 1.48
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene (2001) 1.47
Mapping of the molecular determinants involved in the interaction between eps15 and AP-2. Cancer Res (1997) 1.46
Shc products are substrates of erbB-2 kinase. Oncogene (1993) 1.46
Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest (1997) 1.45
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood (1998) 1.45
Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol (1999) 1.40
Eps15R is a tyrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated internalization. J Biol Chem (1998) 1.38
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene (1995) 1.38
Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity (1999) 1.37
Recognition specificity of individual EH domains of mammals and yeast. EMBO J (1998) 1.36
Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization. Mol Biol Cell (1999) 1.36
Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood (1999) 1.35
Synthesis and secretion of proteins resembling platelet-derived growth factor by human glioblastoma and fibrosarcoma cells in culture. Proc Natl Acad Sci U S A (1985) 1.33
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res (2001) 1.33
N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res (1993) 1.33
Transgenic analysis of a 100-kb human beta-globin cluster-containing DNA fragment propagated as a bacterial artificial chromosome. Blood (1999) 1.32
Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A (2000) 1.30
The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood (1996) 1.29
Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J (1996) 1.27
A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Oncogene (1996) 1.26
Isolation of cDNAs encoding finger proteins and measurement of the corresponding mRNA levels during myeloid terminal differentiation. Nucleic Acids Res (1988) 1.25